Table 1 Baseline characteristics of patients
From: How to manage synchronous endometrial and ovarian cancer patients?
Variables | Total (N = 47) | DP (N = 28) | Meta (N = 19) | P-value |
|---|---|---|---|---|
Age (med, min-max) | 52 (24–70) | 50 (24–69) | 54 (39–70) | 0.263 |
Approach | 1.000 | |||
Laparoscopy | 9 (19.1) | 5 (17.9) | 4 (21.1) | |
Laparotomy | 38 (80.9) | 23 (82.1) | 15 (78.9) | |
PLND | 0.685 | |||
No | 7 (14.9) | 5 (17.9) | 2 (10.5) | |
Yes | 40 (85.1) | 23 (82.1) | 17 (89.5) | |
PALND | 1.000 | |||
No | 12 (25.5) | 7 (25.0) | 5 (26.3) | |
Yes | 35 (74.5) | 21 (75.0) | 14 (73.7) | |
LVS I | 0.417 | |||
No | 40 (85.1) | 25 (89.3) | 15 (78.9) | |
Yes | 7 (14.9) | 3 (10.7) | 4 (21.1) | |
Endocervix-invasion | 0.381 | |||
No | 42 (89.4) | 26 (92.9) | 16 (84.2) | |
Yes | 5 (10.6) | 2 (7.1) | 3 (15.8) | |
Pelvic_peritoneum_invasion | 0.485 | |||
No | 36 (76.6) | 20 (71.4) | 16 (84.2) | |
Yes | 11 (23.4) | 8 (28.6) | 3 (15.8) | |
Endometrial FIGO stage | <.001 | |||
1 | 30 (63.8) | 24 (85.8) | 6 (31.6) | |
2 | 2 (4.3) | 2 (7.1) | 0 (0.0) | |
3 | 12 (25.5) | 2 (7.1) | 10 (52.6) | |
4 | 3 (6.4) | 0 (0.0) | 3 (15.8) | |
Ovarian FIGO stage | miss = 12 | 0.038 | ||
1 | 19 (54.2) | 16 (57.1) | 3 (42.9) | |
2 | 8 (22.9) | 8 (28.6) | 0 (0.0) | |
3 | 7 (20.0) | 4 (14.3) | 3 (42.9) | |
4 | 1 (2.9) | 0 (0.0) | 1 (14.2) | |
Endometrial histology | 0.018 | |||
Non-endometrioid | 11 (23.4) | 3 (10.7) 2 serous 1 clear cell | 8 (42.1) 5 serous 1 clear 1 mixed 1 carcinosarcoma | |
Endometrioid | 36 (76.6) | 25 (89.3) | 11 (57.9) | |
Ovarian histology | 0.210 | |||
Non-endometrioid | 22 (46.8) | 11 (39.3) 5 serous 2 clear 2 seromucinous 1 mucinous 1 carcinosarcoma | 11 (57.9) 8 serous 2 mixed 1 carcinosarcoma | |
Endometrioid | 25 (53.2) | 17 (60.7) | 8 (42.1) | |
Endometrial FIGO grade | miss = 8 | 0.002 | ||
1 | 17 (43.6) | 16 (61.5) | 1 (7.7) | |
2 | 11 (28.2) | 6 (23.1) | 5 (38.5) | |
3 | 11 (28.2) | 4 (15.4) | 7 (53.8) | |
Ovarian grade | miss = 7 | 0.056 | ||
1 | 15 (37.5) | 13 (50.0) | 2 (14.3) | |
2 | 13 (32.5) | 8 (30.8) | 5 (35.7) | |
3 | 12 (30.0) | 5 (19.2) | 7 (50.0) | |
Adjuvant chemotherapy | 0.685 | |||
No | 7 (14.9) | 5 (17.9) | 2 (10.5) | |
Yes | 40 (85.1) | 23 (82.1) | 17 (89.5) | |
Adjuvant radiotherapy | 1.000 | |||
No | 42 (89.4) | 25 (89.3) | 17 (89.5) | |
Yes | 5 (10.6) | 3 (10.7) | 2 (10.5) |